KR20040023741A - 퍼옥시좀 증식제 응답성 수용체 δ의 활성화제 - Google Patents
퍼옥시좀 증식제 응답성 수용체 δ의 활성화제 Download PDFInfo
- Publication number
- KR20040023741A KR20040023741A KR10-2004-7002008A KR20047002008A KR20040023741A KR 20040023741 A KR20040023741 A KR 20040023741A KR 20047002008 A KR20047002008 A KR 20047002008A KR 20040023741 A KR20040023741 A KR 20040023741A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- carbon atoms
- compound
- atom
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
시험화합물 | 투여량(mg/kg/b.i.d.) | HDL 콜레스테롤 증가율(대조군에 대한 %) |
실시예 4 | 10 | 176 |
실시예 10 | 10 | 134 |
GW-501516 | 10 | 149 |
Claims (18)
- 하기 일반식 I 로 표시되는 화합물 또는 그의 염:(식 중, R1은 치환기로서 탄소수 1∼8의 알킬기, 할로겐원자로 치환된 탄소수 1∼8의 알킬기, 탄소수 1∼8의 알콕시기, 할로겐원자로 치환된 탄소수 1∼8의 알콕시기, 탄소수 2∼8의 알케닐기, 탄소수 2∼8의 알키닐기, 할로겐원자, 탄소수 2∼7의 아실기, 벤조일기, 수산기, 니트로기, 아미노기, 페닐기 혹은 피리딜기에서 선택되는 기 또는 원자를 가질 수도 있는 페닐기, 나프틸기, 피리딜기, 티에닐기, 푸릴기, 퀴놀릴기 혹은 벤조티에닐기를 나타내고, R2는 탄소수 1∼8의 알킬기, 할로겐원자로 치환된 탄소수 1∼8의 알킬기, 탄소수 2∼8의 알케닐기, 탄소수 2∼8의 알키닐기, 3∼7원 환의 시클로알킬기 혹은 3∼7원 환의 시클로알킬기로 치환된 탄소수 1∼8의 알킬기, 또는 치환기로서 탄소수 1∼8의 알킬기, 할로겐원자로 치환된 탄소수 1∼8의 알킬기, 탄소수 1∼8의 알콕시기, 할로겐원자로 치환된 탄소수 1∼8의 알콕시기, 탄소수 2∼8의 알케닐기, 탄소수 2∼8의 알키닐기, 할로겐원자, 탄소수 2∼7의 아실기, 벤조일기, 수산기, 니트로기, 아미노기, 페닐기 혹은 피리딜기에서 선택되는 기 또는 원자를 가질 수도 있는 페닐기, 나프틸기 혹은 피리딜기로치환된 탄소수 1∼6개의 알킬기를 나타내고, A 는 산소원자, 황원자 또는 NR9를 나타내고, 여기에서 R9는 수소원자 또는 탄소수 1∼8의 알킬기를 나타내고, X 는 치환기로서 탄소수 1∼8의 알킬기, 탄소수 1∼8의 알콕시기 또는 수산기에서 선택되는 기를 가질 수도 있고, 그리고 2중 결합을 함유할 수도 있는 탄소수 1∼8의 알킬렌쇄를 나타내고, Y 는 C(=O), C(=N-OR10), CH(OR11), CH=CH, C≡C 또는 C(=CH2) 를 나타내고, 여기에서 R10, R11은 수소원자 또는 탄소수 1∼8의 알킬기를 나타내고, R3, R4및 R5는 수소원자, 탄소수 1∼8의 알킬기, 할로겐원자로 치환된 탄소수 1∼8의 알킬기, 탄소수 1∼8의 알콕시기, 할로겐원자로 치환된 탄소수 1∼8의 알콕시기, 탄소수 2∼8의 알케닐기, 탄소수 2∼8의 알키닐기, 할로겐원자, 탄소수 2∼7의 아실기, 벤조일기, 수산기, 니트로기, 아미노기, 페닐기 또는 피리딜기를 나타내고, B 는 CH 또는 질소원자를 나타내고, Z 는 산소원자 또는 황원자를 나타내고, R6및 R7은 수소원자, 탄소수 1∼8의 알킬기 또는 할로겐원자로 치환된 탄소수 1∼8의 알킬기를 나타내고, 그리고 R8은 수소원자 또는 탄소수 1∼8의 알킬기를 나타낸다. 단, R3, R4및 R5의 적어도 하나는 수소원자가 아님).
- 제 1 항에 있어서, R1이 치환기로서 탄소수 1∼8의 알킬기, 1∼3개의 할로겐원자로 치환된 탄소수 1∼8의 알킬기, 탄소수 1∼8의 알콕시기, 1∼3개의 할로겐원자로 치환된 탄소수 1∼8의 알콕시기, 탄소수 2∼8의 알케닐기, 탄소수 2∼8의 알키닐기, 할로겐원자, 탄소수 2∼7의 아실기, 벤조일기, 수산기, 니트로기, 아미노기, 페닐기 혹은 피리딜기에서 선택되는 기 또는 원자를 가질 수도 있는 페닐기인 화합물 또는 그의 염.
- 제 1 항 또는 제 2 항에 있어서, R2가 탄소수 2∼8의 알킬기인 화합물 또는 그의 염.
- 제 1 항 내지 제 3 항 중 어느 한 항에 있어서, R1의 치환위치가 2위치인 화합물 또는 그의 염.
- 제 1 항 내지 제 4 항 중 어느 한 항에 있어서, A 가 산소원자 혹은 황원자인 화합물 또는 그의 염.
- 제 1 항 내지 제 5 항 중 어느 한 항에 있어서, X 가 탄소수 1∼8의 알킬렌쇄인 화합물 또는 그의 염.
- 제 1 항 내지 제 6 항 중 어느 한 항에 있어서, Y 가 C(=O) 인 화합물 또는그의 염.
- 제 1 항 내지 제 7 항 중 어느 한 항에 있어서, R3, R4및 R5가 수소원자, 탄소수 1∼8의 알킬기 혹은 할로겐원자로 치환된 탄소수 1∼8의 알킬기인 화합물 또는 그의 염.
- 제 1 항 내지 제 8 항 중 어느 한 항에 있어서, B 가 CH 인 화합물 또는 그의 염.
- 제 1 항 내지 제 9 항 중 어느 한 항에 있어서, Z 가 산소원자인 화합물 또는 그의 염.
- 제 1 항 내지 제 10 항 중 어느 한 항에 있어서, R6및 R7이 수소원자 또는 탄소수 1∼4의 알킬기인 화합물 또는 그의 염.
- 제 1 항 내지 제 11 항 중 어느 한 항에 있어서, R8이 수소원자인 화합물 또는 그의 염.
- 제 1 항에 있어서, R1이 치환기로서 탄소수 1∼8의 알킬기, 할로겐원자로 치환된 탄소수 1∼8의 알킬기, 탄소수 1∼8의 알콕시기, 할로겐원자로 치환된 탄소수 1∼8의 알콕시기, 탄소수 2∼8의 알케닐기, 탄소수 2∼8의 알키닐기, 할로겐원자, 탄소수 2∼7의 아실기, 벤조일기, 수산기, 니트로기, 아미노기, 페닐기 혹은 피리딜기에서 선택되는 기 또는 원자를 가질 수도 있는 페닐기 또는 나프틸기이고, R2가 탄소수 2∼8의 알킬기이고, A 가 산소원자 또는 황원자이고, X 가 치환기로서 탄소수 1∼8의 알킬기를 가질 수도 있고, 그리고 2중 결합을 포함할 수도 있는 탄소수 1∼8의 알킬렌쇄이고, Y 가 C(=O), CH=CH 또는 C(=CH2) 이고, R3, R4및 R5가 수소원자, 탄소수 1∼8의 알킬기, 할로겐원자로 치환된 탄소수 1∼8의 알킬기, 탄소수 1∼8의 알콕시기, 할로겐원자로 치환된 탄소수 1∼8의 알콕시기, 탄소수 2∼8의 알케닐기, 탄소수 2∼8의 알키닐기, 할로겐원자, 탄소수 2∼7의 아실기, 벤조일기, 수산기, 니트로기, 아미노기, 페닐기 또는 피리딜기이고, B 가 CH 이고, Z 가 산소원자 또는 황원자이고, R6및 R7이 수소원자 또는 탄소수 1∼8의 알킬기이고, 그리고 R8이 수소원자 또는 탄소수 1∼8의 알킬기인 화합물 또는 그의 염.
- 제 13 항에 있어서, X 가 탄소수 1∼8의 알킬렌쇄인 화합물 또는 그의 염.
- 제 13 항 또는 제 14 항에 있어서, R1의 치환위치가 2위치인 화합물 또는 그의 염.
- 제 13 항 내지 제 15 항 중 어느 한 항에 있어서, R8이 수소원자인 화합물 또는 그의 염.
- 제 13 항 내지 제 16 항 중 어느 한 항에 있어서, R3, R4및 R5중, 수소원자 이외의 치환기가 -Z-CR6R7CO2R8에 대해 오르토위치로 치환되어 있는 화합물 또는 그의 염.
- 제 1 항 내지 제 17 항 중 어느 한 항에 기재된 화합물 또는 그의 염을 유효성분으로 함유하는 퍼옥시좀 증식제 응답성 수용체 δ의 활성화제.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001243734 | 2001-08-10 | ||
JPJP-P-2001-00243734 | 2001-08-10 | ||
PCT/JP2002/007897 WO2003016291A1 (fr) | 2001-08-10 | 2002-08-02 | Activateur du recepteur $g(d) sensible au proliferateur de peroxysome |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040023741A true KR20040023741A (ko) | 2004-03-18 |
KR100901683B1 KR100901683B1 (ko) | 2009-06-08 |
Family
ID=19073779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047002008A KR100901683B1 (ko) | 2001-08-10 | 2002-08-02 | 퍼옥시좀 증식제 응답성 수용체 δ의 활성화제 |
Country Status (16)
Country | Link |
---|---|
US (3) | US7265137B2 (ko) |
EP (1) | EP1424330B1 (ko) |
JP (3) | JP4421895B2 (ko) |
KR (1) | KR100901683B1 (ko) |
CN (1) | CN1330641C (ko) |
AT (1) | ATE526319T1 (ko) |
AU (1) | AU2002323776B2 (ko) |
BR (1) | BRPI0211844B8 (ko) |
CA (1) | CA2457054C (ko) |
CY (1) | CY1112130T1 (ko) |
DK (1) | DK1424330T3 (ko) |
ES (1) | ES2372813T3 (ko) |
IL (2) | IL160304A0 (ko) |
MX (1) | MXPA04001258A (ko) |
PT (1) | PT1424330E (ko) |
WO (1) | WO2003016291A1 (ko) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105551B2 (en) * | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
PT1424330E (pt) * | 2001-08-10 | 2011-12-22 | Nippon Chemiphar Co | Activador do receptor ä responsivo a proliferadores peroxissomais |
IL161351A0 (en) * | 2001-10-12 | 2004-09-27 | Nippon Chemiphar Co | ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR delta |
US20070037882A1 (en) * | 2003-04-22 | 2007-02-15 | Astellas Pharma Inc. | Remedy for cerebral neurodegenerative diseases using ppar agonist |
SI1667964T1 (sl) | 2003-09-19 | 2009-12-31 | Janssen Pharmaceutica Nv | 4-((fenoksialkil)tio)-fenoksiocetne kisline in analogi |
WO2005060958A1 (en) * | 2003-12-19 | 2005-07-07 | Kalypsys, Inc. | (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes |
US7554974B2 (en) * | 2004-03-09 | 2009-06-30 | Tekelec | Systems and methods of performing stateful signaling transactions in a distributed processing environment |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
JP2007536343A (ja) | 2004-05-05 | 2007-12-13 | ノボ ノルディスク アクティーゼルスカブ | Pparアゴニストとしてのフェノキシ酢酸誘導体 |
WO2005105736A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
JPWO2006041197A1 (ja) * | 2004-10-14 | 2008-05-22 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤活性化受容体δの活性化剤 |
CN101166720A (zh) * | 2005-02-28 | 2008-04-23 | 日本化学医药株式会社 | 过氧化物酶体增殖剂激活受体δ的激活剂 |
BRPI0610177A2 (pt) * | 2005-05-25 | 2016-11-29 | Nippon Chemiphar Co | composto ou um sal do mesmo, e, ativador para receptor ativado por proliferador de peroxissomo |
ES2372617T3 (es) | 2005-06-30 | 2012-01-24 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de ppar-delta. |
RU2008108221A (ru) * | 2005-09-07 | 2009-10-20 | Плекссикон, Инк. (Us) | Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом) |
JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
BRPI0616465A2 (pt) * | 2005-09-29 | 2011-06-21 | Sanofi Aventis | derivados de fenil-[1,2,4]-oxadiazol-5-ona com grupo fenila, bem como seu uso, composição farmacêutica compreendo os mesmos e processo de preparação da referida composição farmacêutica |
CA2631390C (en) | 2005-12-22 | 2014-03-11 | Per Sauerberg | Phenoxy acetic acids as ppar delta activators |
US7649098B2 (en) * | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
EP1999098A2 (en) | 2006-03-09 | 2008-12-10 | High Point Pharmaceuticals, LLC | Compounds that modulate ppar activity, their preparation and use |
UY30288A1 (es) * | 2006-04-18 | 2007-08-31 | Janssen Pharmaceutica Nv | Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol |
RU2435764C2 (ru) | 2006-04-18 | 2011-12-10 | Ниппон Кемифар Ко., Лтд. | АГЕНТ, АКТИВИРУЮЩИЙ РЕЦЕПТОР, АКТИВИРУЕМЫЙ ПРОЛИФЕРАТОРАМИ ПЕРОКСИСОМ δ |
AU2013202514B2 (en) * | 2006-04-18 | 2015-09-17 | Nippon Chemiphar Co., Ltd. | Activating agent for peroxisome proliferator activated receptor delta |
WO2007122970A1 (ja) * | 2006-04-20 | 2007-11-01 | Osaka University | 核内受容体に結合するリガンド |
US8193228B2 (en) | 2006-10-20 | 2012-06-05 | Merck Sharp & Dohme Corp. | Substituted imidazole as bombesin receptor subtype-3 modulators |
CA2667003A1 (en) | 2006-10-20 | 2008-05-02 | Merck & Co., Inc. | Substituted imidazoles as bombesin receptor subtype-3 modulators |
EP2083822A2 (en) | 2006-10-20 | 2009-08-05 | Merck & Co., Inc. | Substituted imidazoles as bombesin receptor subtype-3 modulators |
FR2910893A1 (fr) * | 2006-12-29 | 2008-07-04 | Genfit Sa | Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazolyl)-phenyl-propan-1-one substitues, preparations et utilisations. |
JP5247686B2 (ja) * | 2007-05-21 | 2013-07-24 | 千寿製薬株式会社 | PPARδアゴニスト含有医薬 |
TW200920355A (en) * | 2007-09-06 | 2009-05-16 | Lexicon Pharmaceuticals Inc | Compositions and methods for treating immunological and inflammatory diseases and disorders |
WO2009078981A2 (en) * | 2007-12-13 | 2009-06-25 | Sri International | Ppar-delta ligands and methods of their use |
NZ588612A (en) * | 2008-04-15 | 2012-08-31 | Nippon Chemiphar Co | Benzothiophen derivatives as activators of peroxisome proliferator activated receptor (PPAR) |
MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010064633A1 (ja) * | 2008-12-01 | 2010-06-10 | 田辺三菱製薬株式会社 | チアゾール環を含むカルボン酸誘導体およびその医薬用途 |
JP2012116753A (ja) * | 2009-03-26 | 2012-06-21 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤活性化受容体の活性化剤 |
MX2012001932A (es) * | 2009-08-14 | 2012-03-14 | Nippon Chemiphar Co | Uso de ligandos ppar delta para el tratamiento o prevencion de enfermedades relacionadas con metabolismo/produccion de inflamacion o energia. |
CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
KR101668514B1 (ko) | 2011-02-25 | 2016-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체 |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
EP3043789B1 (en) | 2013-09-09 | 2020-07-08 | vTv Therapeutics LLC | Use of a ppar-delta agonists for treating muscle atrophy |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN105237487B (zh) * | 2015-10-19 | 2017-10-10 | 安徽中医药大学 | 含川芎嗪基查尔酮芳氧烷酸类化合物、制备方法及其应用 |
JPWO2017195875A1 (ja) * | 2016-05-12 | 2019-03-22 | 日本ケミファ株式会社 | 創傷治療剤 |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
GB9027023D0 (en) | 1990-12-12 | 1991-01-30 | Wellcome Found | Anti-atherosclerotic aryl compounds |
HUT64023A (en) | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
CA2090283A1 (en) * | 1992-02-28 | 1993-08-29 | Nobuyuki Hamanaka | Phenoxyacetic acid derivatives |
JP3722855B2 (ja) * | 1993-09-14 | 2005-11-30 | 武田薬品工業株式会社 | 2,4−オキサゾリジンジオン誘導体およびそれを含んでなる医薬 |
GB9426448D0 (en) | 1994-12-30 | 1995-03-01 | Wellcome Found | Process |
AU714054B2 (en) | 1995-01-06 | 1999-12-16 | Toray Industries, Inc. | Benzene-fused heterocyclic derivatives and use of the same |
CA2171702A1 (en) | 1995-03-14 | 1996-09-15 | Takashi Sohda | Benzofuran compounds and their use |
WO1996035688A1 (fr) | 1995-05-08 | 1996-11-14 | Nippon Chemiphar Co., Ltd. | Derives de 2,4-thiazolidinedione ou d'oxazolidinedione et agent hypoglycemique |
ATE216384T1 (de) | 1996-01-22 | 2002-05-15 | Fujisawa Pharmaceutical Co | Thiazolylbenzofuranderivate und pharmazeutische zusammensetzungen die sie enthalten |
JP2002503202A (ja) | 1996-02-02 | 2002-01-29 | メルク エンド カンパニー インコーポレーテッド | 抗糖尿病薬 |
US20020032330A1 (en) | 1996-12-24 | 2002-03-14 | Yutaka Nomura | Propionic acid derivatives |
AU8355998A (en) * | 1997-07-24 | 1999-02-16 | Yamanouchi Pharmaceutical Co., Ltd. | Medicinal compositions with cholesterol-lowering effect |
US6589969B1 (en) | 1998-10-16 | 2003-07-08 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
DK1206457T3 (da) | 1999-08-27 | 2004-02-16 | Lilly Co Eli | Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER |
TW200528436A (en) * | 1999-09-22 | 2005-09-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
JP2001354671A (ja) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
US6787552B2 (en) * | 2000-08-11 | 2004-09-07 | Nippon Chemiphar Co., Ltd. | PPAR delta activators |
GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
WO2002076957A1 (fr) * | 2001-03-23 | 2002-10-03 | Nippon Chemiphar Co.,Ltd. | Activateur de recepteur active par les proliferateurs du peroxysome |
GB0111523D0 (en) | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
PT1424330E (pt) | 2001-08-10 | 2011-12-22 | Nippon Chemiphar Co | Activador do receptor ä responsivo a proliferadores peroxissomais |
-
2002
- 2002-08-02 PT PT02755779T patent/PT1424330E/pt unknown
- 2002-08-02 ES ES02755779T patent/ES2372813T3/es not_active Expired - Lifetime
- 2002-08-02 IL IL16030402A patent/IL160304A0/xx unknown
- 2002-08-02 JP JP2003521216A patent/JP4421895B2/ja not_active Expired - Fee Related
- 2002-08-02 WO PCT/JP2002/007897 patent/WO2003016291A1/ja active Application Filing
- 2002-08-02 US US10/486,783 patent/US7265137B2/en not_active Expired - Lifetime
- 2002-08-02 AU AU2002323776A patent/AU2002323776B2/en not_active Expired
- 2002-08-02 DK DK02755779.2T patent/DK1424330T3/da active
- 2002-08-02 BR BR0211844A patent/BRPI0211844B8/pt not_active IP Right Cessation
- 2002-08-02 AT AT02755779T patent/ATE526319T1/de active
- 2002-08-02 CA CA2457054A patent/CA2457054C/en not_active Expired - Lifetime
- 2002-08-02 MX MXPA04001258A patent/MXPA04001258A/es active IP Right Grant
- 2002-08-02 KR KR1020047002008A patent/KR100901683B1/ko active IP Right Grant
- 2002-08-02 CN CNB028201892A patent/CN1330641C/zh not_active Expired - Lifetime
- 2002-08-02 EP EP02755779A patent/EP1424330B1/en not_active Expired - Lifetime
-
2004
- 2004-02-10 IL IL160304A patent/IL160304A/en unknown
-
2007
- 2007-07-31 US US11/888,493 patent/US7652045B2/en active Active
- 2007-07-31 US US11/888,492 patent/US7648999B2/en not_active Expired - Lifetime
-
2009
- 2009-02-16 JP JP2009032919A patent/JP2009102442A/ja active Pending
- 2009-09-03 JP JP2009203393A patent/JP5097180B2/ja not_active Expired - Fee Related
-
2011
- 2011-12-02 CY CY20111101199T patent/CY1112130T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US7648999B2 (en) | 2010-01-19 |
DK1424330T3 (da) | 2012-01-16 |
JP4421895B2 (ja) | 2010-02-24 |
CA2457054A1 (en) | 2003-02-27 |
JP5097180B2 (ja) | 2012-12-12 |
PT1424330E (pt) | 2011-12-22 |
ES2372813T3 (es) | 2012-01-26 |
US7652045B2 (en) | 2010-01-26 |
CA2457054C (en) | 2011-10-11 |
WO2003016291A1 (fr) | 2003-02-27 |
US20050054674A1 (en) | 2005-03-10 |
JPWO2003016291A1 (ja) | 2004-12-02 |
IL160304A (en) | 2010-12-30 |
JP2009102442A (ja) | 2009-05-14 |
BR0211844A (pt) | 2004-08-31 |
BRPI0211844B1 (pt) | 2019-08-27 |
MXPA04001258A (es) | 2005-06-06 |
IL160304A0 (en) | 2004-07-25 |
KR100901683B1 (ko) | 2009-06-08 |
EP1424330A4 (en) | 2004-10-27 |
ATE526319T1 (de) | 2011-10-15 |
JP2009280622A (ja) | 2009-12-03 |
EP1424330B1 (en) | 2011-09-28 |
CN1568316A (zh) | 2005-01-19 |
BRPI0211844B8 (pt) | 2021-05-25 |
US20080009631A1 (en) | 2008-01-10 |
CY1112130T1 (el) | 2015-11-04 |
CN1330641C (zh) | 2007-08-08 |
US7265137B2 (en) | 2007-09-04 |
AU2002323776B2 (en) | 2008-07-31 |
EP1424330A1 (en) | 2004-06-02 |
US20080009525A1 (en) | 2008-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100901683B1 (ko) | 퍼옥시좀 증식제 응답성 수용체 δ의 활성화제 | |
JP4790969B2 (ja) | ペルオキシソーム増殖剤応答性受容体δの活性化剤 | |
JP4226005B2 (ja) | Ppar活性化化合物及びこれを含有する医薬組成物 | |
JP4157381B2 (ja) | ペルオキシソーム増殖剤応答性受容体の活性化剤 | |
US6498174B1 (en) | Substituted oxazoles and thiazoles derivatives as hPPARγ and hPPARα activators | |
KR100933652B1 (ko) | 페록시좀 증식제 응답성 수용체 δ의 활성화제 | |
KR20090006853A (ko) | 페록시좀 증식제 활성화 수용체 δ 의 활성화제 | |
CZ20033037A3 (cs) | Karboxylové kyselinou odvozené od substituovaných oxazolových derivátů pro použití jako PPAR-alfa a -gama aktivátory při léčbě diabetu | |
JP2006516254A (ja) | Pparモジュレータとしての縮合ヘテロ環誘導体 | |
JPWO2002046176A1 (ja) | ペルオキシソーム増殖剤応答性受容体の活性化剤 | |
CZ300654B6 (cs) | Thiazolové a oxazolové deriváty a jejich farmaceutické použití | |
KR20010034586A (ko) | 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제 | |
JP2005529077A (ja) | ペルオキシソーム増殖因子活性化受容体調節物質 | |
KR20100132070A (ko) | 퍼옥시좀 증식제 활성화 수용체의 활성화제 | |
KR20070053622A (ko) | PPARγ와 PPARα의 활성을 항진시키는 신규화합물, 그것의 제조방법및 그것을 함유한 약제 조성물 | |
CZ20033252A3 (en) | Oxazol/ thiazol-derivatives activators of the hppar-alpha receptor | |
JPWO2006126714A1 (ja) | ペルオキシソーム増殖剤活性化受容体の活性化剤 | |
MXPA01001419A (en) | SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS hPPAR GAMMA AND hPPAR ALPHA ACTIVATORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130524 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140523 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150526 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160520 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170526 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180529 Year of fee payment: 10 |